[
  {
    "id": "1",
    "title": "AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases",
    "tags": [
      "Irritable bowel syndrome",
      "Fecal microbiota",
      "Clostridioides difficile",
      "Chronic Diseases"
    ],
    "publishedBy": "American Gastroenterological Association",
    "publishedDate": "6th March, 2024",
    "authors": [
      "Anne F Peery",
      "Colleen R Kelly",
      "Dina Kao",
      "Byron P Vaughn",
      "Benjamin Lebwohl",
      "Siddharth Singh",
      "Aamer Imdad",
      "Osama Altayar"
    ],
    "reviewedBy": "Dr. Kamal Sharma, Senior Interventional Cardiologist, SAL Hospital",
    "views": 1220,

    "keyHighlights": [
      "Fecal microbiota-based therapies, including fecal microbiota transplant and FDA-approved therapies, are the focus of guidelines developed by the American Gastroenterological Association (AGA).",
      "The AGA’s guideline aims to provide recommendations for the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection, severe to fulminant C difficile infection, inflammatory bowel diseases (including pouchitis), and irritable bowel syndrome.",
      "Developed using the GRADE framework, the guideline panel prioritized clinical questions, identified patient-centered outcomes, and conducted evidence synthesis.",
      "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
      "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
      "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ],

    "sponsorBanners": [
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "This page is supported by Pfizer as part of their educational initiative",
        "description": "Pfizer, a trailblazer in healthcare, offers innovative medications like Lipitor and Viagra, setting new benchmarks in patient-centric solutions and medical excellence."
      },
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "Another Educational Support Message",
        "description": "This is another educational message from a healthcare partner."
      }
    ],

     "watchSection": {
    "videoImage": "/assets/video.webp",
    "changeData": [
       "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
       "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
       "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ]
},
    "contemporaryData": {
      "rowLabels": ["Patients", "Clinicians", "Policy"],
      "strongRecommendation": [
        "Most individuals in this situation would want the recommended course of action, and only a small proportion would not.",
        "Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.",
        "The recommendation can be adopted as policy in most situations."
      ],
      "conditionalRecommendation": [
        "The majority of individuals in this situation would want the suggested course of action, but many would not.",
        "Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their values and preferences.",
        "Policymaking will require substantial debate and involvement of various stakeholders."
      ]
    },

    
    "academicData": {
         "referenceLink": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
         "referenceText": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
         "supportImage": "../assets/pfizer.webp",
         "description": "Pfizer, founded in 1849, is a global pharmaceutical leader known for groundbreaking contributions to healthcare. Our guidelines, supported by Pfizer's legacy, prioritize evidence-based practices for optimal patient care, reflecting a shared commitment to advancing medical standards."
    },

    "comments": [
      {
        "name": "Dr. Nivs K.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user2.webp"
      },
      {
        "name": "Dr. Rudra S.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user3.webp"
      }
      
    ]
  },


   {
    "id": "2",
    "title": "Initial management of hyperglycemia in adults with type 2 diabetes mellitus",
    "tags": [
      "Irritable bowel syndrome",
      "Fecal microbiota",
      "Clostridioides difficile",
      "Chronic Diseases"
    ],
    "publishedBy": "American Gastroenterological Association",
    "publishedDate": "6th March, 2024",
    "authors": [
      "Anne F Peery",
      "Colleen R Kelly",
      "Dina Kao",
      "Byron P Vaughn",
      "Benjamin Lebwohl",
      "Siddharth Singh",
      "Aamer Imdad",
      "Osama Altayar"
    ],
    "reviewedBy": "Dr. Kamal Sharma, Senior Interventional Cardiologist, SAL Hospital",
    "views": 1220,

    "keyHighlights": [
      "Fecal microbiota-based therapies, including fecal microbiota transplant and FDA-approved therapies, are the focus of guidelines developed by the American Gastroenterological Association (AGA).",
      "The AGA’s guideline aims to provide recommendations for the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection, severe to fulminant C difficile infection, inflammatory bowel diseases (including pouchitis), and irritable bowel syndrome.",
      "Developed using the GRADE framework, the guideline panel prioritized clinical questions, identified patient-centered outcomes, and conducted evidence synthesis.",
      "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
      "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
      "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ],

    "sponsorBanners": [
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "This page is supported by Pfizer as part of their educational initiative",
        "description": "Pfizer, a trailblazer in healthcare, offers innovative medications like Lipitor and Viagra, setting new benchmarks in patient-centric solutions and medical excellence."
      },
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "Another Educational Support Message",
        "description": "This is another educational message from a healthcare partner."
      }
    ],

    "watchSection": {
    "videoImage": "/assets/video.webp",
    "changeData": [
       "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
       "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
       "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ]
},

    "contemporaryData": {
      "rowLabels": ["Patients", "Clinicians", "Policy"],
      "strongRecommendation": [
        "Most individuals in this situation would want the recommended course of action, and only a small proportion would not.",
        "Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.",
        "The recommendation can be adopted as policy in most situations."
      ],
      "conditionalRecommendation": [
        "The majority of individuals in this situation would want the suggested course of action, but many would not.",
        "Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their values and preferences.",
        "Policymaking will require substantial debate and involvement of various stakeholders."
      ]
      
    },

    "academicData": {
        "referenceLink": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
        "referenceText": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
        "supportImage": "../assets/pfizer.webp",
        "description": "Pfizer, founded in 1849, is a global pharmaceutical leader known for groundbreaking contributions to healthcare. Our guidelines, supported by Pfizer's legacy, prioritize evidence-based practices for optimal patient care, reflecting a shared commitment to advancing medical standards."
  },

    "comments": [
      {
        "name": "Dr. Nivs K.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user2.webp"
      },
      {
        "name": "Dr. Rudra S.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user3.webp"
      }
    ]
  },

  
   {
    "id": "3",
    "title": "2023 EULAR recommendations on imaging in diagnosis and management",
    "tags": [
      "Irritable bowel syndrome",
      "Fecal microbiota",
      "Clostridioides difficile",
      "Chronic Diseases"
    ],
    "publishedBy": "American Gastroenterological Association",
    "publishedDate": "6th March, 2024",
    "authors": [
      "Anne F Peery",
      "Colleen R Kelly",
      "Dina Kao",
      "Byron P Vaughn",
      "Benjamin Lebwohl",
      "Siddharth Singh",
      "Aamer Imdad",
      "Osama Altayar"
    ],
    "reviewedBy": "Dr. Kamal Sharma, Senior Interventional Cardiologist, SAL Hospital",
    "views": 1220,

    "keyHighlights": [
      "Fecal microbiota-based therapies, including fecal microbiota transplant and FDA-approved therapies, are the focus of guidelines developed by the American Gastroenterological Association (AGA).",
      "The AGA’s guideline aims to provide recommendations for the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection, severe to fulminant C difficile infection, inflammatory bowel diseases (including pouchitis), and irritable bowel syndrome.",
      "Developed using the GRADE framework, the guideline panel prioritized clinical questions, identified patient-centered outcomes, and conducted evidence synthesis.",
      "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
      "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
      "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ],

    "sponsorBanners": [
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "This page is supported by Pfizer as part of their educational initiative",
        "description": "Pfizer, a trailblazer in healthcare, offers innovative medications like Lipitor and Viagra, setting new benchmarks in patient-centric solutions and medical excellence."
      },
      {
        "image": "../assets/bannerpfizer.webp",
        "title": "Another Educational Support Message",
        "description": "This is another educational message from a healthcare partner."
      }
    ],
    
    "watchSection": {
    "videoImage": "/assets/video.webp",
    "changeData": [
       "The guideline panel made 7 recommendations, including the use of fecal microbiota-based therapies in specific scenarios such as recurrent C difficile infection and severe or fulminant cases not responding to standard antibiotics.",
       "Recommendations vary based on the immunocompetence of patients, suggesting select use of therapies in certain populations and against their use in severely immunocompromised individuals.",
       "While fecal microbiota-based therapies are effective for preventing recurrent C difficile in select patients, they are not yet recommended for other gastrointestinal conditions except within the context of clinical trials."
    ]
},

    "contemporaryData": {
      "rowLabels": ["Patients", "Clinicians", "Policy"],
      "strongRecommendation": [
        "Most individuals in this situation would want the recommended course of action, and only a small proportion would not.",
        "Most individuals should receive the intervention. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.",
        "The recommendation can be adopted as policy in most situations."
      ],
      "conditionalRecommendation": [
        "The majority of individuals in this situation would want the suggested course of action, but many would not.",
        "Recognize that different choices will be appropriate for individual patients and that you must help each patient arrive at a management decision consistent with his or her values and preferences. Decision aids may be useful in helping individuals to make decisions consistent with their values and preferences.",
        "Policymaking will require substantial debate and involvement of various stakeholders."
      ]
      
    },

    "academicData": {
       "referenceLink": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
       "referenceText": "https://pubmed.ncbi.nlm.nih.gov/38395525/#",
        "supportImage": "../assets/pfizer.webp",
        "description": "Pfizer, founded in 1849, is a global pharmaceutical leader known for groundbreaking contributions to healthcare. Our guidelines, supported by Pfizer's legacy, prioritize evidence-based practices for optimal patient care, reflecting a shared commitment to advancing medical standards."
    },

    "comments": [
      {
        "name": "Dr. Nivs K.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user2.webp"
      },
      {
        "name": "Dr. Rudra S.",
        "text": "Lorem ipsum dolor sit amet, onsectetur adipiscing elit. Vestibulum efficitur justo vel massa luctus, non hendrerit arcu p",
        "time": "3 Days ago",
        "avatar": "../assets/user3.webp"
      }
    ]
  }
]
